Tempest Therapeutics(TPST) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update - Unveiled new positive survival data for amezalpat (TPST-1120) in randomized first-line hepatocellular carcinoma ("HCC)" study demonstrating: • Survival benefit maintained across key subpopulations • a six-month improvement over control arm in median survival • a strong 0.65 hazard ratio, maintained since 0.59 observed 10 months earlier - Advancing amezalpat towards a pivotal Phase 3 trial in first-line HCC - Pl ...